Shortage of Actiq lozenges and Instanyl nasal spray (immediate-release fentanyl citrate)

Actiq lozenges and Instanyl nasal spray are both licensed for the treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. This document provides information on available alternatives, although it should be noted that bioavailablility across products is not equivalent and patients should not be converted on a microgram per microgram basis from one product to another.

Anaesthesia and painCancersFentanylNewsShortages and discontinuationsShortages, Discontinuations and Patent Expiries

Attachments